AMLX Amylyx Pharmaceuticals
- 1.640
- -0.040-2.38%
- 1.630
- -0.010-0.59%
Amylyx Pharmaceuticals News
ALS Therapy Market Seen Increasing to Nearly $1.3B by 2029
Analysts Conflicted on These Healthcare Names: Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals Inc (AMLX) and Vaxcyte (PCVX)
Amylyx Pharmaceuticals(AMLX.US) Officer Sells US$19,654.35 in Common Stock
$Amylyx Pharmaceuticals(AMLX.US)$ Officer Mazzariello Gina sold 10,455 shares of common stock on May 15, 2024 at an average price of $1.8799 for a total value of $19,654.35.Source: Announcement What i
Amylyx Pharmaceuticals(AMLX.US) Director Buys US$9,436.03 in Common Stock
$Amylyx Pharmaceuticals(AMLX.US)$ Director Quimi Daphne purchased 5,000 shares of common stock on May 14, 15, 2024 at an average price of $1.8872 for a total value of $9,436.03.Source: Announcement Wh
Amylyx Pharmaceuticals Is Maintained at Neutral by Mizuho
Amylyx Pharmaceuticals Is Maintained at Neutral by Mizuho
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Wave Life Sciences (WVE) and GoodRx Holdings (GDRX)
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), IN8bio (INAB) and Privia Health Group (PRVA)
Express News | Amylyx Pharmaceuticals Inc : Mizuho Cuts Target Price to $3 From $4
Bank of America Securities Keeps Their Hold Rating on Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals Reports Q1 2024 Financial Results
Breaking Down Amylyx Pharma: 9 Analysts Share Their Views
Amylyx Pharma (NASDAQ:AMLX) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The following table summarizes their recent ratings, sheddi
Express News | HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $8 Price Target
Amylyx Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 314.51% HC Wainwright & Co. → $8 Reiterates Buy → Buy 04/11/2024 55.44% Baird $4 → $3 Maintains
Q1 2024 Amylyx Pharmaceuticals Inc Earnings Call
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2024 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2024 Earnings Call Transcript
Express News | Amylyx Pharma Cash, Cash Equivalents And Short-term Investments Of $373.3M At March 31, 2024 Provides Expected Cash Runway Into 2026
Express News | Amylyx Pharma Q1 2024 GAAP EPS $(1.75)May Not Be Comparable To $0.01 Estimate, Sales $88.643M Miss $98.346M Estimate
Amylyx Pharmaceuticals | 10-Q: Quarterly report
Express News | Amylyx Pharmaceuticals Inc - Amylyx Expects to Initiate Clinical Trial of Amx0114 in ALS in Second Half of 2024
Express News | Amylyx Pharmaceuticals Inc - Interim Analysis From Orion Study of Amx0035 in Progressive Supranuclear Palsy Continues to Be Expected in Mid-2025
Analysis
Price Target
No Data
